Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Date:12/10/2007

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone (VAD). This study was conducted by the Intergroupe Francophone du Myelome (IFM) cooperative group and CHU Nantes and selected for an oral presentation at the American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Ga., December 8-11, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The very high complete and near complete remission rate of 21 percent with this induction therapy significantly improved post-transplantation complete remission rates. This led to a decrease in patients requiring a second transplant," said Professor Jean-Luc Harousseau, M.D., Hospital Hotel- Dieu Nantes and Principal Investigator of the trial. "Historically, regimens used as induction therapy prior to stem cell transplantation (SCT) produced low complete remission rates and offered minimal incremental benefit post- transplantation."

Results from the large clinical trial were presented by Professor Harousseau:
-- As induction therapy prior to SCT, the VcD arm demonstrated a complete

remission (CR, including immunofixation positive and negative) rate of

21 percent compared to 8 percent with VAD (p<0.0001)

-- Of the 404 patients who proceeded to SCT, the VcD arm demonstrated a

post-transplantation complete remission (CR, including immunofixation

positive and negative) rate of 41 percent comp
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
2. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
3. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
4. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
5. HCV and HBV spreading more slowly among injection drug users in San Francisco
6. Microbiotic technology developed for microinjection of zebrafish embryos
7. Pill Equals Injection in Preventing Clots After Hip Replacement
8. Multiple corticosteroid injections in pregnant women may increase cerebral palsy
9. Consumer Safety Alert on Fat Dissolving Injections
10. MultiVu Video Feed: FDA Approves DORIBAX(TM) (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract Infections
11. Ultrasound-guided injections help ease chronic Achilles tendon pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...y lead to new therapies for preterm labor , ...ers say they,ve found the switch that activates th...h, a finding that may lead to therapies for preter...binds the protein IP on the surface of these uteri...during pregnancy. , But researchers from Dartm...
(Date:11/21/2008)..., Pa., Nov. 21 During ...or Edward G. Rendell today remembered Lieutenant G...r, an important partner in public service, and a t..., , "As the first woman elected lieutenant g...servant," said Governor Rendell. "Her family and h...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
(Date:11/21/2008)...eholders Intend To Vigorously Protect Investment A..., Nov. 21 Dr. Stephen J...amendment to their Schedule 13D with the U.S. Secu...sly filed a 13D disclosing ownership of 11.4% of L...77 LasikPlus fixed-site laser vision correction ce...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...m writing letters of condolence to the next of kin...he latest Medical Journal of Australia.// In an ...e wary of penning a condolence letter to a decease...n, a thoracic and sleep physician at the Wesley Me...
...rnia has done herself and her new born proud. The ...th to a baby that was conceived with a frozen egg ...s given a dismal picture about her chances of havi.... Apparently, her fallopian tubes were blocked. Th...
...omplaints reported over pharmacists’ and pharmacie...sial birth control pill, // the Washington State B...ruling ensures that all pharmacies and pharmacists...less there is concern that the medication might be...
...o embark on an ambitious plan promising up to 99 p...he state is expected to set limits to how much...health insurance. This move is hoped to mean that ...state will be able to afford premiums and vital me...
Other Medicine News:Health News:Health Insurance For Almost Everyone In Massachusetts 2
(Date:11/18/2008)...008 Faces of Influenza survey underscores that mot...nza; Mother and Gold Medalist Kristi Yamaguchi joi...ewswire/ -- While 78 percent of mothers in the Uni...ally life-threatening disease that can strike anyo... get vaccinated this season, according to a new su...
(Date:11/13/2008)...ional Supplements Prior to Surgery, ARLINGTON HEI...ntifying,malnutrition before surgery in massive we...gnificantly decrease surgical complications, accel...t patient energy levels,according to a study in t...rgery(R), the official medical journal of the Amer...
(Date:11/12/2008)...James D. Watson, Marilyn & James Simons and,Sherry...Md., Nov. 12 J. Craig V...g Venter Institute (JCVI), was,awarded the Double ...HL) on,November 6th at a gala event in New York Ci...long with Dr. James D.,Watson for making each of t...
(Date:11/12/2008)...tudy and New Data Suggesting Need for Improved ...Meeting -, EXTON, Pa., Nov. 12 /PRNewswire-FirstC...oday announced the presentation of data from its o...dy Cinryze(TM) C1 inhibitor,therapy successfully t...AE),attacks seen in the study through the date of ...
Breaking Medicine Technology:Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6FDA Extends Review of Genasense 28R 29 NDA Appeal in Chronic Lymphocytic Leukemia 1190 1FDA Extends Review of Genasense 28R 29 NDA Appeal in Chronic Lymphocytic Leukemia 1190 2FDA Extends Review of Genasense 28R 29 NDA Appeal in Chronic Lymphocytic Leukemia 1190 3Schering Plough Reports Top Line Results of the IDEAL Study 1187 1Schering Plough Reports Top Line Results of the IDEAL Study 1187 2Schering Plough Reports Top Line Results of the IDEAL Study 1187 3Schering Plough Reports Top Line Results of the IDEAL Study 1187 4Schering Plough Reports Top Line Results of the IDEAL Study 1187 5Schering Plough Reports Top Line Results of the IDEAL Study 1187 6Schering Plough Reports Top Line Results of the IDEAL Study 1187 7Schering Plough Reports Top Line Results of the IDEAL Study 1187 8Schering Plough Reports Top Line Results of the IDEAL Study 1187 9Selective restraints and reduced medication could reduce nursing home falls says 4 year study 1877 1Selective restraints and reduced medication could reduce nursing home falls says 4 year study 1877 2U S Food Safety 3A Home Grown Problems Abound 9497 1U S Food Safety 3A Home Grown Problems Abound 9497 2U S Food Safety 3A Home Grown Problems Abound 9497 3U S Food Safety 3A Home Grown Problems Abound 9497 4U S Food Safety 3A Home Grown Problems Abound 9497 5U S Food Safety 3A Home Grown Problems Abound 9497 6
Inquire
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie
The IEC CL30 Series from Thermo delivers maximum convenience and exceptional value for your low-speed clinical applications. With its unique AUTO-LOCK rotor exchange system, user-friendly controls, a
The IEC CL10 from Thermo is the ideal centrifuge for your low-speed clinical applications. With its broad choice of rotors, user-friendly controls, and generous sample capacity, the IEC CL10 delivers
Medicine Products: